시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 고급 유전자 편집 기술 시장 분석 및 예측(-2034년) : 유형, 제품, 서비스, 기술, 용도, 최종 사용자, 구성 요소, 프로세스, 스테이지, 솔루션
Advanced Gene Editing Technologies Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Component, Process, Stage, Solutions
상품코드 : 1740631
리서치사 : Global Insight Services LLC
발행일 : 2025년 06월
페이지 정보 : 영문 344 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,606,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,997,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,387,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 고급 유전자 편집 기술 시장 규모는 2024년 14억 달러에서 2034년에는 32억 달러로 확대될것으로 예측되고 CAGR 약 8.7%로 성장할 것으로 전망됩니다. 이 시장은 CRISPR, TALENs, ZFNs 등 정밀 유전자 변형을 위한 도구와 플랫폼을 포함합니다. 이러한 기술은 표적 유전자 변형을 가능하게 하여 치료제, 농업, 합성 생물학 분야에서 혁신적인 잠재력을 제공합니다. 이 시장은 유전체 편집 응용 기술의 발전, 규제 승인, 생물공학 연구에 대한 투자 증가로 인해 성장하고 있으며, 맞춤형 의료와 작물 개선 분야의 혁신을 촉진하고 있습니다.

시장 개요 :

고급 유전자 편집 기술 시장은 정밀 의학과 농업 생물공학에 대한 수요 증가로 인해 강력한 성장을 보이고 있습니다. CRISPR-Cas9 부문은 전통적인 유전자 편집 방법에 비해 뛰어난 효율성, 비용 효율성, 사용 편의성으로 인해 선두를 차지하고 있습니다. 이 부문의 우위는 유전적 연구와 치료 응용 분야에서 널리 채택되면서 기술적 우위와 유전적 질환 해결을 위한 혁신적 잠재력을 강조하고 있습니다. 기반 편집과 프라임 편집과 같은 신흥 세분 시장은 향상된 정밀도와 오프-타겟 효과를 제공하며 주목받고 있습니다. 이러한 혁신은 더 정확한 유전체 수정 가능성을 열어 개인화 의학과 지속 가능한 농업의 새로운 길을 열 것으로 예상됩니다. 또한 CRISPR 기반 진단 기술의 등장으로 질병의 신속하고 정확한 검출이 가능해져 의료 서비스 제공과 공중 보건 결과에 큰 영향을 미칠 수 있는 새로운 기회가 열리고 있습니다.

주요 동향 및 촉진요인 :

고급 유전자 편집 기술 시장은 여러 주요 억제요인과 도전 과제에 직면하고 있습니다. 주요 우려 사항은 윤리적 및 규제적 장벽으로, 기술의 신속한 채택을 방해합니다. 이러한 기술은 엄격한 심사를 받으며, 이는 승인 지연과 시장 진입을 초래합니다. 또한 개발 및 구현 비용이 높다는 점은 접근성을 제한하며, 특히 개발도상 지역에서 더욱 두드러집니다. 이 재정적 장벽은 자금력이 풍부한 기관의 참여를 제한해 혁신과 경쟁을 억제합니다. 또 다른 도전 과제는 의도하지 않은 유전적 결과의 가능성으로, 이해관계자들 사이에서 안전성 우려를 제기합니다. 이 불확실성은 광범위한 연구와 모니터링을 필요로 하며, 이는 비용과 시장 출시 시간을 추가로 증가시킵니다. 또한 표준화된 프로토콜의 부재는 다양한 산업 및 응용 분야에 걸쳐 이러한 기술을 통합하는 것을 복잡하게 만듭니다. 마지막으로, 공공 인식과 수용도는 잘못된 정보와 윤리적 논쟁에 영향을 받아 변동성이 높습니다. 이는 저항이나 수요 감소로 이어져 시장 성장과 투자 잠재력에 영향을 미칠 수 있습니다.

주요 억제요인 및 도전 :

고급의 유전자 편집 기술 시장은 몇 가지 현저한 억제요인과 과제에 직면하고 있습니다. 구현에 드는 비용이 높기 때문에 특히 개발도상 지역에서는 이용이 제한됩니다. 이해관계자들 사이에서 안전성에 대한 우려가 높아지고 있다는 점입니다. 야생과 응용 분야에서 이러한 기술의 통합이 복잡해지고 있습니다.

목차

제1장 고급 유전자 편집 기술 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 고급 유전자 편집 기술 시장 전망

제5장 고급 유전자 편집 기술 시장 전략

제6장 고급 유전자 편집 기술 시장 규모

제7장 고급 유전자 편집 기술 시장 : 유형별

제8장 고급 유전자 편집 기술 시장 : 제품별

제9장 고급 유전자 편집 기술 시장 : 서비스별

제10장 고급 유전자 편집 기술 시장 : 기술별

제11장 고급 유전자 편집 기술 시장 : 용도별

제12장 고급 유전자 편집 기술 시장 : 최종 사용자별

제13장 고급 유전자 편집 기술 시장 : 구성 요소별

제14장 고급 유전자 편집 기술 시장 : 프로세스별

제15장 고급 유전자 편집 기술 시장 : 스테이지별

제16장 고급 유전자 편집 기술 시장 : 솔루션별

제17장 고급 유전자 편집 기술 시장 : 지역별

제18장 경쟁 구도

제19장 기업 프로파일

HBR
영문 목차

영문목차

Advanced Gene Editing Technologies Market is anticipated to expand from $1.4 billion in 2024 to $3.2 billion by 2034, growing at a CAGR of approximately 8.7%. The market encompasses tools and platforms for precise genetic modifications, including CRISPR, TALENs, and ZFNs. These technologies enable targeted gene alterations, offering transformative potential in therapeutics, agriculture, and synthetic biology. The market is driven by advancements in genome editing applications, regulatory approvals, and increasing investment in biotechnology research, fostering innovations in personalized medicine and crop enhancement.

Market Overview:

The Advanced Gene Editing Technologies Market is experiencing robust expansion, primarily driven by the escalating demand for precision medicine and agricultural biotechnology. The CRISPR-Cas9 segment is at the forefront, owing to its unparalleled efficiency, cost-effectiveness, and ease of use compared to traditional gene-editing methods. This segment's dominance is bolstered by its widespread adoption in genetic research and therapeutic applications, highlighting its technological superiority and transformative potential in addressing genetic disorders. Emerging sub-segments such as base editing and prime editing are gaining traction, offering enhanced precision and reduced off-target effects. These innovations are poised to revolutionize the market by enabling more accurate genomic modifications, thereby opening new avenues for personalized medicine and sustainable agriculture. Additionally, the advent of CRISPR-based diagnostics presents a burgeoning opportunity, promising rapid and precise disease detection, which could significantly impact healthcare delivery and public health outcomes.

Market Segmentation
TypeCRISPR-Cas9, TALENs, Zinc Finger Nucleases, Meganucleases, Base Editing, Prime Editing
ProductReagents and Kits, Software and Systems, Instruments, Cell Lines
ServicesGene Synthesis, Cell Line Engineering, Custom Assay Development, Consultation and Advisory
TechnologyGenome Editing, Gene Silencing, Gene Knockout, Gene Knock-in
ApplicationBiomedical Research, Agriculture, Therapeutics, Drug Discovery, Diagnostics
End UserPharmaceutical Companies, Biotechnology Firms, Academic and Research Institutes, Contract Research Organizations
ComponentGuide RNA, Vectors, Plasmids, Proteins
ProcessIn Vivo, In Vitro
StageResearch and Development, Clinical Trials, Commercialization
SolutionsGene Editing Platforms, Data Analysis Tools, Quality Control Solutions, Regulatory Compliance Solutions

Geographical Overview:

The advanced gene editing technologies market is witnessing remarkable growth across various regions. North America stands at the forefront, propelled by cutting-edge research and robust funding from both public and private sectors. The presence of leading biotechnology firms and academic institutions further accelerates advancements in gene editing applications. Europe follows closely, with significant investments in research and development. The region's regulatory environment supports innovation while ensuring ethical considerations. This balance fosters a thriving market for gene editing technologies, particularly in agriculture and healthcare. In the Asia Pacific, rapid technological advancements and increasing government support drive market expansion. Countries like China and Japan are investing heavily in biotech research, positioning themselves as key players in the global gene editing landscape. Latin America is emerging as a promising market, with growing interest in agricultural biotechnology to address food security challenges. The region's focus on sustainable development aligns well with the potential of gene editing technologies. The Middle East and Africa are recognizing the transformative potential of gene editing. Investments in biotechnology research are increasing, with a focus on addressing regional health and agricultural needs. This burgeoning interest is expected to drive future market growth in these regions.

Recent Developments:

The Advanced Gene Editing Technologies Market has witnessed notable developments in recent months. CRISPR Therapeutics and Vertex Pharmaceuticals have announced the completion of their regulatory submissions for the gene-editing therapy exa-cel, targeting sickle cell disease and beta-thalassemia, marking a significant milestone in gene therapy. In a strategic move, Editas Medicine has entered into a collaboration with Azzur Group to streamline the development and manufacturing processes of its gene-editing therapies, aiming to enhance efficiency and scalability. Beam Therapeutics has successfully secured $200 million in a recent funding round, underscoring investor confidence in its base-editing technology and its potential to revolutionize genetic medicine. Intellia Therapeutics has partnered with Kyverna Therapeutics to explore novel gene-editing applications in autoimmune diseases, expanding the scope of CRISPR-based therapies. Furthermore, the European Union has introduced new regulatory guidelines to expedite the approval process for advanced gene-editing technologies, aiming to foster innovation while ensuring safety and efficacy. These developments highlight the dynamic nature of the market and the increasing momentum towards transformative genetic therapies.

Key Companies:

Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics, Sangamo Therapeutics, Precision Bio Sciences, Caribou Biosciences, Cellectis, Poseida Therapeutics, Graphite Bio, Recombinetics, Tessera Therapeutics, e Genesis, Inscripta, Synthego, Cibus, Mammoth Biosciences, Gen Edit, Locus Biosciences, Ori Gene Technologies

Key Trends and Drivers:

The advanced gene editing technologies market is experiencing robust growth due to several emerging trends and drivers. The increasing prevalence of genetic disorders and the rising demand for personalized medicine are key drivers of this market. Researchers are leveraging gene editing to develop targeted therapies, enhancing treatment efficacy and reducing side effects. This trend is expected to continue as precision medicine gains traction globally. Another significant trend is the advancement in CRISPR technology, which has revolutionized gene editing by providing a more efficient and cost-effective tool for genetic manipulation. This has spurred innovation across various applications, including agriculture, where gene editing is used to enhance crop resilience and nutritional value. The regulatory landscape is also evolving, with governments worldwide recognizing the potential of gene editing technologies and streamlining approval processes. Moreover, collaborations between academic institutions and biotechnology companies are accelerating research and development activities, leading to faster commercialization of new products. The growing investment in biotechnology research, coupled with technological advancements, is expected to drive market growth further. As public awareness and acceptance of gene editing increase, the market is poised for significant expansion, presenting lucrative opportunities for stakeholders.

Key Restraints and Challenges:

The Advanced Gene Editing Technologies Market is encountering several prominent restraints and challenges. A primary concern is the ethical and regulatory hurdles that impede swift adoption. These technologies often face stringent scrutiny, delaying approvals and market entry. Additionally, the high cost of development and implementation limits accessibility, particularly in developing regions. This financial barrier restricts participation to well-funded entities, stifling innovation and competition. Another challenge is the potential for unintended genetic consequences, raising safety concerns among stakeholders. This uncertainty necessitates extensive research and monitoring, further increasing costs and time to market. Moreover, there is a lack of standardized protocols, which complicates the integration of these technologies across different sectors and applications. Lastly, public perception and acceptance remain variable, influenced by misinformation and ethical debates. This can lead to resistance or reduced demand, affecting market growth and investment potential.

Sources:

National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), Genome Canada, National Human Genome Research Institute (NHGRI), European Molecular Biology Laboratory (EMBL), Biotechnology and Biological Sciences Research Council (BBSRC), Wellcome Trust Sanger Institute, National Academy of Sciences, National Center for Biotechnology Information (NCBI), International Society for Stem Cell Research (ISSCR), American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), International Genomics Consortium (IGC), Cold Spring Harbor Laboratory, Massachusetts Institute of Technology (MIT) - Broad Institute, University of California, Berkeley - Innovative Genomics Institute, Harvard University - Department of Genetics, CRISPR 2023 Conference, International Conference on Genomics and Molecular Biology, Advances in Genome Editing Conference, World Congress on Genetics, International Symposium on Genomics and Bioinformatics

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Advanced Gene Editing Technologies Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Advanced Gene Editing Technologies Market Outlook

5: Advanced Gene Editing Technologies Market Strategy

6: Advanced Gene Editing Technologies Market Size

7: Advanced Gene Editing Technologies Market, by Type

8: Advanced Gene Editing Technologies Market, by Product

9: Advanced Gene Editing Technologies Market, by Services

10: Advanced Gene Editing Technologies Market, by Technology

11: Advanced Gene Editing Technologies Market, by Application

12: Advanced Gene Editing Technologies Market, by End User

13: Advanced Gene Editing Technologies Market, by Component

14: Advanced Gene Editing Technologies Market, by Process

15: Advanced Gene Editing Technologies Market, by Stage

16: Advanced Gene Editing Technologies Market, by Solutions

17: Advanced Gene Editing Technologies Market, by Region

18: Competitive Landscape

19: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기